The efficacy and safety profiles of these therapies are still under investigation.389 A notable study by Parkhurst et al. in 2011 examined the use of TCR-engineered T cells targeting CEA in patients with treatment-resistant CRC. Here, CEACAM5 is linked to colorectal carcinoma.